Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
Holding DE:NOVA?
Track your performance easily
NOVA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€81.00 - €140.00
Previous Close€118.5
Volume28.00
Average Volume (3M)857.00
Market Cap
€524.41B
Enterprise Value€523.98B
Total Cash (Recent Filing)kr30.23B
Total Debt (Recent Filing)kr27.01B
Price to Earnings (P/E)44.1
Beta0.25
Next Earnings
Nov 06, 2024EPS Estimate
€0.8Last Dividend Ex-Date
Aug 16, 2024Dividend Yield0.78%
Share Statistics
EPS (TTM)2.70
Shares Outstanding4,462,229,293
10 Day Avg. Volume617
30 Day Avg. Volume857
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.96
Price to Sales (P/S)17.01
Price to Cash Flow (P/CF)103.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€126.76Price Target Upside6.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Novo Nordisk News
Bulls Say, Bears Say
Bulls Say
Business FundamentalsThe fundamentals of Novo's business and growth story are firmly intact.
Clinical DataPh 1 data highlights potentially best-in-class oral efficacy from Novo's Amycretin, demonstrating placebo-adjusted mean change in body weight of 9.2% at the 50mg dose and 11.9% at the 2x 50mg dose at 12 weeks.
Market OpportunityThe large opportunity of the obesity market leaves plenty of room for multiple players.
Bears Say
Clinical Trial FailureAcquired asset, ocedurenone, fails in pre-specified interim analysis for Ph 3 CLARION-CKD trial.
R&D ExpenseHigher-than-expected R&D expense included a DKK 5.7B ocedurenone impairment contributing to a bottom line miss.
Supply ConstraintsObesity Care notably underperformed with Wegovy still impacted by supply constraints amidst strong demand.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
1.63% Mutual Funds
5.03% Other Institutional Investors
93.34% Public Companies and
Individual Investors
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €81.00 and its highest was €140.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Currently, no data Available
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 07, 2024. The company reported €0.593 earnings per share for the quarter, missing the consensus estimate of €0.638 by -€0.045.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of €0.34 which represents an annual dividend yield of 0.78%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is €0.8.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.593 in its last earnings report, missing expectations of €0.638. Following the earnings report the stock price went down -7.983%.
Which hedge fund is a major shareholder of Novo Nordisk?
Among the largest hedge funds holding Novo Nordisk’s share is Fisher Asset Management LLC. It holds Novo Nordisk’s shares valued at 2B.
---
Novo Nordisk Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€126.76 (6.97% Upside)
€126.76 (6.97% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 82%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.63%
12-Months-Change
Fundamentals
Return on Equity
88.62%
Trailing 12-Months
Asset Growth
29.05%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
NOVA Company Deck
---
NOVA Earnings Call
Q2 2024
0:00 / 0:00
---
NOVA Stock 12 Month Forecast
Average Price Target
€126.76
▲(6.97% Upside)
Technical Analysis
Best Analysts Covering NOVA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+22.30%
reiterated a buy rating last month
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +22.30% per trade.
---